Novartis and the University of Pennsylvania have entered an exclusive global collaboration to research, develop and commercialize chimeric antigen receptor (CAR) immunotherapies for the treatment of cancer. The parties have also established a new R&D facility on the Penn campus, called the Center for Advanced Cellular Therapies (CACT).   As part of the transaction, Novartis acquired exclusive rights to CART-19, an investigational therapy currently being studied by Penn in a clinical trial. C...